科汉斯生命科学公司任命乌曼·沃拉为执行董事长和集团首席执行官,自2026年5月1日起生效. Cohance Lifesciences appoints Umang Vohra as Executive Chairman and Group CEO effective May 1, 2026.

科汉斯生命科学公司任命前Cipla首席执行官Umang Vohra担任执行董事长和集团首席執行官,自2026年5月1日起生效,以推动增长. Cohance Lifesciences appointed former Cipla CEO Umang Vohra as Executive Chairman and Group CEO effective May 1, 2026, to drive growth. 公司的股价在宣布之后升了20%. The company, backed by Advent, saw its shares surge 20% following the announcement. 维维克·沙玛辞职, 但在过渡期间仍担任顾问. Vivek Sharma steps down but remains as an advisor through the transition.